Certara offers predictive science and informatics solutions that enable cross-disciplinary and translational approaches to drug development.
Nearly half of drug candidates entering into pre-clinical development will be lost due to lack of safety. PredictFX™ is a modeling and simulation suite that provides improved opportunities to identify, monitor, and address safety issues earlier in the process by predicting the off-target pharmacology and associated side effect profile of a drug lead compound from its 2D chemical structure.
Using PredictFX, scientists engaged at any stage of the drug discovery and development process can identify safety risks, thus better managing attrition. Based on off-target predictions, chemistry efforts can be focused and targeted on the areas with the best chance of success in pre-clinical and clinical safety, and biological and safety evaluation can be focused on the areas of greatest risk.
Scientists can easily enhance predictive safety models further with PredictFX by incorporating in-house chemical and biological data to ensure that models cover their company’s proprietary chemistry, and that poor compounds are recognized early, reducing attrition effects in the pre-clinical safety stage.
Additionally, PredictFX can be used in the context of drug repurposing to identify new therapeutic applications for a failed development candidate, thus rescuing lost investment.
The PredictFX suite considers drug selectivity and safety from multiple viewpoints, revealing the relationships between the chemical structure, the pharmacological profile, and the resultant side effect profile. The PredictFX suite consists of two (2) modules, which, when used together, these modules can be used to predict the link between side effects and target profile:
PredictFX is supported for Red Hat Enterprise Linux 5 and 6, and requires OpenBabel v2.2.+ to be installed as a prerequisite.
Explore some of our recent webinars